Wang XH, Li L, Holscher C, Pan YF, Chen XR, Qi JS
Patient support programs and talking with healthcare providers may help people find options to continue treatment when needed
J., Yang, Z., Doupis, J., Ahn, C
Months 6 to 12: Continued weight loss and sustained metabolic improvement
With significant or rapid weight loss, particularly when driven by GLP-1 drugs, several mechanisms converge: Loss of underlying fat volume removes structural support Collagen and elastin fibres become stretched and fragmented Speed of weight loss outpaces skin contraction While some rebound occurs naturally, significant laxity can be permanent, especially after large weight reductions
The FDA labels for semaglutide products note that mean increases in resting heart rate of 1-4 beats per minute have been observed, with some patients experiencing larger increases